Higher‐dose versus standard‐dose prophylactic anticoagulation in hospitalized patients with COVID‐19

No benefit in all-cause mortality 1 in 45 were helped (reduced venous thromboembolism) No benefit in all-cause mortality, stroke, myocardial infarction, systemic arterial embolism 2.2% lower risk of venous thromboembolism 1 in 101 were harmed (increased risk of major bleeding) 1 in 18 were harmed (increased risk of any bleeding) 1% increased risk of major bleeding 5.3% increased risk of any bleeding Coronavirus disease 2019 (COVID-19) is a...